Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects

NCT01802918 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01802918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01802918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
February 18, 2013
Completion date
November 21, 2013
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus